# AstraZeneca completes agreement to divest its commercial rights to Seroquel

- Link: https://www.directorstalkinterviews.com/astrazeneca-completes-agreement-to-divest-its-commercial-rights-to-seroquel/412800926
- Published: 2019-12-16T07:09:10+00:00
- Author: Amilia Stone

**AstraZeneca** ([LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
has completed an agreement to divest its commercial rights to _Seroquel_ and _Seroquel
XR_ in Europe and Russia to Cheplapharm Arzneimittel GmbH.

**Financial considerations**

Under the terms of the agreement, AstraZeneca has received a payment of $178m from
Cheplapharm. The Company may also receive future sales-contingent payments of up
to $61m. The upfront payment will be reported in AstraZeneca’s financial statements
within Other Operating Income & Expense in the fourth quarter of 2019.

Pursuant to Listing Rule 10.4.1R (notification of class 2 transactions), the gross
book value of assets subject to the divestment as at 31 December 2018 was nil. In
the year to 31 December 2018, the aggregate profit before tax attributable to _Seroquel_
and _Seroquel XR_ in the relevant territories was $86m. The consideration was paid
in cash and the proceeds will be used for general corporate purposes.

**About _Seroquel_**

_Seroquel_ and _Seroquel XR_ are atypical anti-psychotic medicines with antidepressant
properties. The main indications for _Seroquel_ are the treatment of schizophrenia
and bipolar disorder. _Seroquel XR_ is also approved in some markets for major depressive
disorder and generalised anxiety disorder.

AstraZeneca previously divested the rights to _Seroquel_ and _Seroquel XR_ in the
UK, Japan and other major international markets. AstraZeneca also agreed to divest
the rights to the medicines in the US and Canada to Cheplapharm earlier in 2019.

Share on:
